News|Articles|November 11, 2026

Afimetoran Meets Primary End Point Across 3 Doses in Phase 2 SLE Trial

Afimetoran achieved SRI-4 response rates of 64.1% to 67.8% vs 34.4% with placebo in a phase 2 SLE trial.

Oral afimetoran, an investigational once-daily inhibitor of Toll-like receptors (TLR) 7 and 8, met the primary end point across all 3 evaluated doses in a phase 2 trial involving patients with active systemic lupus erythematosus (SLE).¹

At week 48, SLE Responder Index-4 (SRI-4) response rates were 67.8% with afimetoran 2.5 mg, 64.1% with 10 mg, and 66.1% with 30 mg, compared with 34.4% with placebo (P <.001 for each dose).¹

, of the University of California San Diego, presented the findings during a late-breaking oral session at the American College of Rheumatology (ACR) Convergence 2026 in Orlando, Florida. The detailed findings follow topline results announced by Beeline Medicines in September 2026.

Afimetoran Phase 2 Trial Design and Primary End Point Results

The global, randomized, double-blind, placebo-controlled, dose-ranging trial (NCT04895696) enrolled 248 adults aged 18 to 70 years with active SLE despite background treatment.¹

Eligible patients met Systemic Lupus International Collaborating Clinics (SLICC) classification criteria, had at least 1 positive autoantibody, and demonstrated a hybrid SLE Disease Activity Index (hSLEDAI) score ≥6, including a clinical hSLEDAI score ≥4. Enrollment was enriched for patients with joint and/or rash involvement. Participants also required a British Isles Lupus Assessment Group (BILAG)-2004 grade A score or at least 2 grade B scores.

Investigators randomized patients to receive once-daily afimetoran 2.5 mg (n = 60), 10 mg (n = 64), or 30 mg (n = 62), or placebo (n = 62), for 48 weeks. Treatment was administered alongside background standard-of-care medications, including oral corticosteroids with a mandatory taper, antimalarials, and/or conventional immunosuppressants.

Overall, 76.6% of participants completed 48 weeks, and baseline characteristics were generally balanced across treatment groups.¹

All 3 doses met the primary end point of SRI-4 response at week 48, with similar response rates across the evaluated dose range.

Secondary Outcomes Across Disease Activity, Skin, and Joints

Secondary end points were directionally consistent with the primary outcome, with numerical differences favoring afimetoran across measures of disease activity, corticosteroid use, and skin and joint involvement.¹,²

According to results released by Beeline Medicines, BILAG-based Composite Lupus Assessment (BICLA) response rates ranged from 38.7% to 50.8% across afimetoran doses, compared with 27.9% with placebo. Lupus Low Disease Activity State (LLDAS) was achieved by 35.6% to 39.1% of afimetoran-treated patients, compared with 21.3% receiving placebo.²

At week 48, 71.9% to 75.0% of patients receiving afimetoran reached or maintained a corticosteroid dose ≤7.5 mg/day, compared with 50.0% receiving placebo.

Among patients with active skin disease at baseline, 57.1% to 66.7% of afimetoran-treated patients achieved at least a 50% improvement in Cutaneous Lupus Erythematosus Disease Area and Severity Index activity scores (CLASI-50), compared with 21.4% receiving placebo.

Among patients with at least 6 active joints at baseline, Joint-50 response rates, reflecting at least a 50% reduction in active joint count, ranged from 61.0% to 77.1% with afimetoran, compared with 42.9% with placebo.²

Physician global assessment and Short Form-36 physical component scores also showed numerically greater improvements with afimetoran.

These secondary findings were exploratory, and the analyses were not adjusted for multiplicity. The numerical differences should therefore not be interpreted as confirmatory evidence of treatment benefit across individual secondary outcomes.

TLR7/8 Inhibition and Safety Findings in SLE

TLR7 and TLR8 are intracellular receptors involved in recognizing single-stranded RNA and activating immune signaling pathways implicated in SLE, including type I interferon production, inflammatory cytokine responses, and autoantibody production.¹

Afimetoran is designed to inhibit both receptors. Earlier phase 1b findings in cutaneous lupus erythematosus demonstrated reductions in type I interferon and TLR7/8-associated gene signatures, alongside improvements in cutaneous disease activity.

In the phase 2 SLE trial, suppression of the type I interferon gene signature was observed by week 2 and sustained through week 48 across all 3 doses. Among patients with abnormal baseline biomarker levels, complement C3 and C4 levels increased, while anti–double-stranded DNA antibody levels decreased.¹,²

Treatment-emergent adverse events occurred in 86.6% of afimetoran-treated patients across the pooled dose groups, compared with 79.0% receiving placebo.

Infections were the most common adverse events, occurring in 60.2% of afimetoran-treated patients and 53.2% of placebo-treated patients. Serious infections occurred in 0% to 3.2% of patients across the individual afimetoran dose groups, compared with 4.8% receiving placebo.²

Treatment-emergent serious adverse events occurred in 5.9% of afimetoran-treated patients, compared with 12.9% receiving placebo. Adverse events leading to treatment discontinuation occurred in 3.2% and 9.7%, respectively.

Drug-related treatment-emergent serious adverse events were reported in 1.1% of afimetoran-treated patients, compared with 6.5% receiving placebo. No deaths were reported during the study.²

Although serious adverse events were numerically less frequent with afimetoran, the phase 2 study was not designed to establish a comparative safety advantage. Larger trials with longer follow-up will be needed to further characterize the safety profile.

Limitations and Next Steps for Afimetoran

The phase 2 trial demonstrated higher SRI-4 response rates with afimetoran than placebo across all 3 evaluated doses. However, the similar response rates across a 12-fold dose range leave questions regarding optimal dose selection.

The absence of multiplicity adjustment limits interpretation of secondary outcomes, while the 48-week study duration does not establish longer-term efficacy or safety. The trial population was also selected for active disease, with enrichment for joint and/or rash involvement, which may limit generalizability to patients with other SLE manifestations.

Beeline Medicines plans to initiate phase 3 development of afimetoran in SLE in 2027. The company has also initiated the phase 2/3 DISCOVERY trial, evaluating afimetoran in adults with active cutaneous lupus erythematosus, with or without systemic manifestations.²

Afimetoran remains investigational and is not approved for any indication.